Comparative Efficacy of Finerenone versus Canagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Matching-Adjusted Indirect Comparison

This study aimed to close an evidence gap concerning the relative efficacy of finerenone versus SGLT2is in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Canagliflozin was selected as a proxy for the SGLT2i class. Patient-level data of two randomized controlled trials (RCTs) o...

Descripció completa

Dades bibliogràfiques

Autors principals:	David Cherney, Kerstin Folkerts, Paul Mernagh, Mateusz Nikodem, Joerg Pawlitschko, Peter Rossing, Neil Hawkins
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2024-07-01
Col·lecció:	Journal of Market Access & Health Policy
Matèries:	chronic kidney disease (CKD) type 2 diabetes (T2D) finerenone canagliflozin sodium glucose cotransporter 2 inhibitors (SGLT2i) matching-adjusted indirect comparison (MAIC)
Accés en línia:	https://www.mdpi.com/2001-6689/12/3/14
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!